Form 4: Penumbra Director O'Rourke Granted 589 RSUs Amid Merger Talk

Penumbra Inc. Director Bridget O'Rourke reported the acquisition of 589 restricted stock units, with vesting tied to continued service and a potential merger with Boston Scientific Corporation.

Summary

• Bridget O'Rourke, a Director of Penumbra Inc. (PEN), acquired 589 restricted stock units (RSUs) on February 13, 2026.
• The RSUs were granted at a price of $0, which is typical for such awards.
• Following this acquisition, Ms. O'Rourke beneficially owns 5,962 shares of Penumbra Common Stock, a portion of which is subject to vesting.
• The RSUs vest in four equal installments on March 31, 2026, June 30, 2026, September 30, 2026, and December 31, 2026, contingent on her continued service as a director.
• A significant condition for vesting is tied to a potential merger: if the closing of the Agreement and Plan of Merger (dated January 14, 2026) with Boston Scientific Corporation and Pinehurst Merger Sub, Inc. occurs, any unvested RSUs will fully vest, also subject to continued service.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as a director's RSU grant aligns their interests with shareholders and the merger clause suggests a significant strategic event is in play, potentially indicating future value creation.

Positives

• Director Bridget O'Rourke received a grant of 589 Restricted Stock Units (RSUs), aligning her interests with long-term shareholder value.
• The vesting schedule incentivizes continued service and commitment to the company's performance.
• The acceleration of vesting upon a merger closing provides a clear incentive for successful completion of the transaction.

Risks

• The vesting of RSUs is contingent on Bridget O'Rourke's continued service as a director, meaning forfeiture if service ceases prematurely.
• The accelerated vesting is dependent on the successful closing of the merger with Boston Scientific Corporation and Pinehurst Merger Sub, Inc., which is not guaranteed.

Future Outlook

The vesting schedule for the RSUs extends through December 31, 2026, indicating a long-term incentive for the director. The explicit mention of a merger agreement with Boston Scientific Corporation suggests a significant corporate event is anticipated, which could accelerate vesting.

Industry Context

StockSavvy.ai notes that RSU grants are a common form of executive and director compensation in the medical device and healthcare technology sectors, aligning leadership incentives with shareholder returns. The mention of a merger with Boston Scientific Corporation, a major player in the medical technology industry, indicates potential consolidation or strategic realignment within the sector, which is a broader trend.

Comparison to Industry Standards

• The grant of 589 RSUs to a director is a standard practice for incentivizing long-term commitment, comparable to similar grants seen at companies like Medtronic or Abbott Laboratories for their non-executive directors, though the specific number varies based on company size and compensation philosophy.
• The $0 acquisition price for RSUs is standard across the industry, as these are typically compensatory grants rather than purchases.
• The inclusion of accelerated vesting upon a change of control (merger) is a common provision in RSU agreements, designed to protect executive and director interests during corporate transitions, similar to provisions observed in merger agreements involving companies like Stryker or Johnson & Johnson.

Stakeholder Impact

• Shareholders: The RSU grant aligns director incentives with shareholder value. The merger clause indicates a potential strategic transaction that could impact share value.
• Employees: No direct impact mentioned, but a merger could have broader implications for employees.
• Management: The RSU grant is a form of management compensation.

Next Steps

• Continued service of Bridget O'Rourke as a director through vesting dates (March 31, 2026, June 30, 2026, September 30, 2026, and December 31, 2026) for RSU vesting.
• Potential closing of the Agreement and Plan of Merger with Boston Scientific Corporation and Pinehurst Merger Sub, Inc., which would trigger accelerated RSU vesting.

Key Dates

Recommendation

While the RSU grant itself is a routine compensation event, the explicit mention of an Agreement and Plan of Merger with Boston Scientific Corporation is a significant development. Investors should hold to await further details on the merger, as its terms and completion will be the primary driver of future stock performance. The RSU grant, with its merger-contingent vesting, suggests management confidence in the transaction.

Keywords

Penumbra Inc, PEN, Bridget O'Rourke, Form 4, SEC Filing, Restricted Stock Units, RSUs, Director Compensation, Insider Trading, Equity Grant, Corporate Governance, Merger, Boston Scientific